期刊
IN VIVO
卷 35, 期 6, 页码 3431-3439出版社
INT INST ANTICANCER RESEARCH
DOI: 10.21873/invivo.12643
关键词
Method comparison; prostate cancer; total PSA; free PSA; hybritech calibration; WHO calibration
The study compared PSA assays from different manufacturers and calibrations, finding that Roche and Beckman tPSA were almost interchangeable, but there were discrepancies in fPSA, indicating a need for greater harmonization efforts.
Background/Aim: Lack of interchangeability between prostate-specific antigen (PSA) assays could have a clinical impact. We compared PSA assays from different manufacturers and calibrations. Patients and Methods: A total of 233 men who underwent prostate biopsy (PSA: 2-10 ng/ml; Beckman Coulter Access (R) Hybritech (R) as reference) were enrolled. Total (tPSA) and free PSA (fPSA) were also measured using the Roche cobas (R) and the Abbott Architect (R) methods. Results: Roche tPSA values were approximate to 1% higher than Beckman, while Abbott values were approximate to 5% lower. Roche had the highest diagnostic sensitivity (92%) compared to Beckman Coulter (87%) and Abbott (85%). Roche fPSA was approximate to 3% lower and Abbott approximate to 17% higher than that of Beckman. For the percentage of fPSA, Roche had the highest sensitivity (98%). Conclusion: Roche cobas (R) and Beckman Coulter Access (R) Hybritech (R) tPSA were almost interchangeable. While the agreement was acceptable for tPSA, this did not happen with fPSA and greater efforts for harmonization are required.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据